Neuroone Medical Technologies is trading at $0.86, down 6.9%; no clear company-specific catalyst has been identified for the October 26, 2026 decline. - Its latest reported announcement was an October 22 purchase order for StereoCED research, but available reporting does not link it to the drop. - Major U.S. indexes were modestly higher, so a broad-market decline does not explain the move. Available information does not establish why shares are falling.